Maximum dosage of rasagiline for Parkinson's disease

Rasagiline (Rasagiline) is a second-generation, potent and selective inhibitor of monoamine oxidase b. Studies in healthy subjects and patients with Parkinson's disease have shown that rasagiline irreversibly inhibits platelet MAO-B. The inhibitory effect lasts for at least 1 week after the last dose. After a single dose of rasagiline 1 mg/day, almost 25-35% inhibition of MAO-B was obtained, while after a single dose of rasagiline 2 mg/day, more than 55% inhibition of MAO-B was obtained. The inhibition rate reached over 90% 3 days after daily administration of rasagiline at a dose of 2 mg/day, and this inhibition level remained unchanged 3 days after administration. Multiple doses of rasagiline at 0.5, 1, and 2 mg daily resulted in complete MAO-B inhibition.